Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Cost of Revenue (2023 - 2025)

Mangoceuticals' Cost of Revenue history spans 3 years, with the latest figure at $2359.0 for Q3 2025.

  • For Q3 2025, Cost of Revenue fell 89.03% year-over-year to $2359.0; the TTM value through Sep 2025 reached $67242.0, down 46.35%, while the annual FY2024 figure was $93296.0, 39.77% down from the prior year.
  • Cost of Revenue for Q3 2025 was $2359.0 at Mangoceuticals, down from $18815.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $53362.0 in Q4 2023 and bottomed at $2359.0 in Q3 2025.
  • The 3-year median for Cost of Revenue is $23753.0 (2023), against an average of $26737.0.
  • The largest YoY upside for Cost of Revenue was 18.96% in 2025 against a maximum downside of 89.03% in 2025.
  • A 3-year view of Cost of Revenue shows it stood at $53362.0 in 2023, then crashed by 60.03% to $21331.0 in 2024, then plummeted by 88.94% to $2359.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Cost of Revenue are $2359.0 (Q3 2025), $18815.0 (Q2 2025), and $24737.0 (Q1 2025).